Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...
This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and ...
Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...
The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results